Tardive Dyskinesia (TD) | AUSTEDO XR® (deutetrabenazine ...
AUSTEDO XR ® (deutetrabenazine) extended-release tablets and AUSTEDO ® (deutetrabenazine) tablets are indicated in adults for the treatment of chorea associated with Huntington’s disease and …
AUSTEDO XR® Medication for Tardive Dyskinesia (TD)
Once-daily AUSTEDO XR® (deutetrabenazine) extended release tablets reduce uncontrollable Tardive Dyskinesia (TD) body movements. See safety info including Boxed Warning.
Austedo (deutetrabenazine): Uses, Side Effects, Dosage Guide
Aug 20, 2025 · Austedo's drug class is a VMAT2 inhibitor (vesicular monoamine transporter 2 inhibitor). Austedo tablets are taken twice daily, and the Austedo XR (extended-release) tablets are taken once …
AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR ...
Nov 7, 2025 · The most common adverse reactions for AUSTEDO (4% and greater than placebo) in controlled clinical studies in patients with tardive dyskinesia were nasopharyngitis and insomnia. …
Austedo Phase 4 Data Shows Reduction in Tardive Dyskinesia ...
Nov 12, 2025 · Austedo standard and XR tablets are currently indicated for adults for the treatment of chorea in Huntington disease and tardive dyskinesia. Austedo is the first VMAT2 inhibitor approved …
Austedo: Regaining Control Over Uncontrolled Movements in ...
Jul 16, 2024 · Austedo (aw-STED-oh) was approved in 2017 and is the first medicine approved to treat both tardive dyskinesia and chorea caused by Huntington’s disease.
Teva Announces AUSTEDO® XR (deutetrabenazine) Extended ...
May 29, 2024 · U.S. FDA approves new one pill, once-daily AUSTEDO XR tablets (30, 36, 42, 48 mg/day) AUSTEDO XR offers more flexibility with the most once-daily doses of any vesicular …
Patients Taking AUSTEDO XR® (deutetrabenazine) - GlobeNewswire
Sep 21, 2025 · The most common adverse reactions for AUSTEDO (4% and greater than placebo) in controlled clinical studies in patients with tardive dyskinesia were nasopharyngitis and insomnia.
AUSTEDO® XR: Tardive Dyskinesia and Huntington's Chorea …
AUSTEDO® XR (deutetrabenazine) extended-release tablets is the first medication approved to treat both tardive dyskinesia and Huntington's disease chorea. See safety info including Boxed Warning.
Austedo XR Approved: A New Treatment Option for Tardive ...
May 30, 2024 · The FDA has approved Austedo XR as a once-daily pill treatment option for tardive dyskinesia and Huntington disease chorea control.